Mm confirmed further treatment and evaluation

Asking for Preferences
Asking for Preferences
Reading File
Finding Sources
Searching PubMed

"multiple myeloma" AND "staging" AND "diagnostic workup"

Finding Sources
Searching PubMed

"multiple myeloma" AND diagnosis AND staging

Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Searching Images

multiple myeloma bone marrow plasma cells lytic lesions skull

Gross pathology photograph of the cranial vault (calvaria) from a 60-year-old male with plasma cell myeloma. The image demonstrates multiple round, punched-out lytic lesions scattered across the skull with destructive osteolysis of the calvarial bone. Lesions are variably sized, ranging from 1 to 4 cm in diameter, and are largely devoid of surrounding sclerosis. The affected bone shows pale, creamy to tan-rose, gelatinous tumor tissue within the radiolucent areas; the interior is soft and hemorrhagic, with scattered dark red foci representing microhemorrhages. The periosteum is disrupted in focal regions, and there is minimal inflammatory reaction. This macroscopic appearance reflects clonal proliferation of immunoglobulin-producing plasma cells occupying medullary spaces and replacing normal bone marrow. Clinically, such skull lesions are highly characteristic of multiple myeloma and can lead to pain, pathologic fracture, and neurological compromise if the skull base or spine is involved. The image provides a visual correlate for the classic punched-out radiolucencies described in hematologic malignancies and should be correlated with serum protein electrophoresis, immunofixation, and bone marrow biopsy. Differential considerations include metastatic skull lesions, Langerhans cell histiocytosis, osteomyelitis, and eosinophilic granuloma. This photograph is often used in educational materials to illustrate gross features of monoclonal gammopathy with skeletal involvement and to aid in teaching macroscopic recognition of myeloma.

Gross pathology photograph of the cranial vault (calvaria) from a 60-year-old male with plasma cell myeloma. The image demonstrates multiple round, punched-out lytic lesions scattered across the skull with destructive osteolysis of the calvarial bone. Lesions are variably sized, ranging from 1 to 4 cm in diameter, and are largely devoid of surrounding sclerosis. The affected bone shows pale, creamy to tan-rose, gelatinous tumor tissue within the radiolucent areas; the interior is soft and hemorrhagic, with scattered dark red foci representing microhemorrhages. The periosteum is disrupted in focal regions, and there is minimal inflammatory reaction. This macroscopic appearance reflects clonal proliferation of immunoglobulin-producing plasma cells occupying medullary spaces and replacing normal bone marrow. Clinically, such skull lesions are highly characteristic of multiple myeloma and can lead to pain, pathologic fracture, and neurological compromise if the skull base or spine is involved. The image provides a visual correlate for the classic punched-out radiolucencies described in hematologic malignancies and should be correlated with serum protein electrophoresis, immunofixation, and bone marrow biopsy. Differential considerations include metastatic skull lesions, Langerhans cell histiocytosis, osteomyelitis, and eosinophilic granuloma. This photograph is often used in educational materials to illustrate gross features of monoclonal gammopathy with skeletal involvement and to aid in teaching macroscopic recognition of myeloma.

This lateral skull radiograph (X-ray) demonstrates the classic 'punched-out' or 'moth-eaten' appearance characteristic of multiple myeloma. The image reveals numerous well-circumscribed, round-to-oval radiolucent (lytic) lesions of varying sizes distributed across the calvarium, including the frontal, parietal, and occipital bones. These lesions show no evidence of peripheral sclerotic margins, indicating aggressive bone resorption without significant reactive bone formation. The calvarial diploe is notably involved, showing a generalized decrease in bone density and disruption of the normal trabecular pattern. Clinical significance of these findings includes the hallmark skeletal manifestations of plasma cell dyscrasias, where monoclonal plasma cells infiltrate the bone marrow, triggering osteoclast activity. This diagnostic image serves as an educational example of hematologic malignancy-associated osteolysis and is a critical component of a skeletal survey for staging conditions like multiple myeloma or metastatic disease.

This lateral skull radiograph (X-ray) demonstrates the classic 'punched-out' or 'moth-eaten' appearance characteristic of multiple myeloma. The image reveals numerous well-circumscribed, round-to-oval radiolucent (lytic) lesions of varying sizes distributed across the calvarium, including the frontal, parietal, and occipital bones. These lesions show no evidence of peripheral sclerotic margins, indicating aggressive bone resorption without significant reactive bone formation. The calvarial diploe is notably involved, showing a generalized decrease in bone density and disruption of the normal trabecular pattern. Clinical significance of these findings includes the hallmark skeletal manifestations of plasma cell dyscrasias, where monoclonal plasma cells infiltrate the bone marrow, triggering osteoclast activity. This diagnostic image serves as an educational example of hematologic malignancy-associated osteolysis and is a critical component of a skeletal survey for staging conditions like multiple myeloma or metastatic disease.

Gross pathology photograph of calvarial skull bones from a 60-year-old male with plasma cell myeloma showing multiple round lytic lesions. The skull base and vault are involved with discrete, punched-out defects ranging approximately 1 to 4 cm in diameter. The lesions are filled with soft, gelatinous red-brown tumor tissue, giving the inner table a slightly eroded appearance and thinning of the surrounding cortex. The overlying periosteum is variably preserved; surrounding diploic spaces may appear expanded and vascularized. The appearance is characteristic of osteolytic activity produced by clonal plasma cells that suppress normal bone formation and promote bone resorption, commonly involving the vertebral column, skull, ribs, pelvis, proximal long bones, and clavicles. In this specimen, the cranial vault bears multiple nodular foci with conspicuous dark hematopoietic plugs and subtle hemorrhagic foci. The gross features correlate with radiographic images of lytic skull lesions seen in multiple myeloma, or plasmacytomas, and reflect high tumor burden. Clinically, these findings support a diagnosis of multiple myeloma in the appropriate systemic context (anemia, hypercalcemia, renal dysfunction, monoclonal protein). Differential diagnoses include metastatic cancer and Langerhans cell histiocytosis. This image is useful for surgical pathology education, gross anatomy training, and radiology-pathology correlation exercises.

Gross pathology photograph of calvarial skull bones from a 60-year-old male with plasma cell myeloma showing multiple round lytic lesions. The skull base and vault are involved with discrete, punched-out defects ranging approximately 1 to 4 cm in diameter. The lesions are filled with soft, gelatinous red-brown tumor tissue, giving the inner table a slightly eroded appearance and thinning of the surrounding cortex. The overlying periosteum is variably preserved; surrounding diploic spaces may appear expanded and vascularized. The appearance is characteristic of osteolytic activity produced by clonal plasma cells that suppress normal bone formation and promote bone resorption, commonly involving the vertebral column, skull, ribs, pelvis, proximal long bones, and clavicles. In this specimen, the cranial vault bears multiple nodular foci with conspicuous dark hematopoietic plugs and subtle hemorrhagic foci. The gross features correlate with radiographic images of lytic skull lesions seen in multiple myeloma, or plasmacytomas, and reflect high tumor burden. Clinically, these findings support a diagnosis of multiple myeloma in the appropriate systemic context (anemia, hypercalcemia, renal dysfunction, monoclonal protein). Differential diagnoses include metastatic cancer and Langerhans cell histiocytosis. This image is useful for surgical pathology education, gross anatomy training, and radiology-pathology correlation exercises.

I now have everything I need for a thorough answer. Here is the full workup and staging guide for confirmed multiple myeloma.

Multiple Myeloma: Post-Confirmation Diagnostic Workup & Staging

Once multiple myeloma is confirmed (i.e., the criteria are met: ≥10% clonal bone marrow plasma cells + M protein + ≥1 myeloma-defining event), the next step is a structured evaluation to characterize disease extent, end-organ damage, cytogenetic risk, and eligibility for transplant. This drives all treatment decisions.

1. Diagnostic Criteria Recap (IMWG)

Myeloma is defined by:
  • ≥10% clonal plasma cells on bone marrow biopsy, AND
  • M protein in serum or urine (except nonsecretory myeloma), AND
  • ≥1 myeloma-defining event (MDE):
    • Hypercalcemia (Ca >1 mg/dL above upper normal or >11 mg/dL)
    • Renal insufficiency (creatinine >2 mg/dL or CrCl <40 mL/min)
    • Anemia (Hb <10 g/dL or >2 g below normal)
    • Bone lesions - ≥1 lytic lesion on skeletal survey, CT, or PET-CT
    • Biomarker MDEs: BM plasma cells ≥60%, serum involved/uninvolved FLC ratio ≥100, or >1 focal lesion on MRI ≥5 mm
These are referred to as CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions) plus biomarker MDEs. - Harrison's Principles of Internal Medicine 22E

2. Laboratory Workup

Serum Studies

TestPurpose
Serum protein electrophoresis (SPEP)Detect and quantify M spike
Serum immunofixation electrophoresis (IFE)Identify immunoglobulin class (IgG, IgA, IgM, IgD, IgE)
Serum free light chains (kappa/lambda ratio)Detect nonsecretory/light-chain myeloma; monitor response
Quantitative immunoglobulinsAssess immunosuppression of uninvolved Ig
CBC with differentialAnemia, cytopenias, rouleaux formation on smear
Comprehensive metabolic panelCreatinine, calcium, albumin, LDH, uric acid
Beta-2 microglobulin (β2M)Key staging marker (ISS)
AlbuminPaired with β2M for ISS staging
LDHElevated = high tumor burden, poor prognosis (R-ISS)
CRPIndirect measure of IL-6 activity
Coagulation studiesFactor X deficiency in amyloid co-occurrence
Serum immunofixation is more sensitive than SPEP - it can detect low M components not visible on electrophoresis. - Harrison's 22E

Urine Studies

  • 24-hour urine protein electrophoresis + IFE - quantify and type Bence Jones protein (free light chains in urine)
  • Spot urine total protein and albumin:creatinine ratio

Bone Marrow Examination

  • Aspirate + trephine biopsy - mandatory; trephine (core) biopsy is preferred for accurate plasma cell percentage when there is discordance with aspirate (use the higher value)
  • Immunohistochemistry with CD138 (syndecan-1) staining confirms clonal plasma cells
  • Flow cytometry: kappa/lambda light chain restriction to establish clonality
  • FISH cytogenetics (or DNA sequencing where available) - essential for risk stratification (see below)

3. Imaging

ModalityNotes
Whole-body low-dose CT (WBLDCT)Preferred first-line imaging; detects lytic lesions, vertebral collapse, pathologic fractures
Whole-body MRIBest for detecting bone marrow infiltration and cord compression; particularly valuable in oligosecretory/nonsecretory myeloma
PET-CT (FDG)Evaluates extramedullary disease, focal lesions, and is useful for response assessment; identifies metabolically active sites
Plain skeletal surveyStill performed in some centers but less sensitive; replaced by CT or MRI in modern practice
PET-CT is especially valuable for staging and for evaluating oligo- or nonsecretory myeloma where M protein is unreliable. - Harrison's 22E
Classic radiographic finding: "punched-out" lytic lesions without sclerotic margins, most common in vertebrae, ribs, skull, pelvis, and proximal long bones.
Lateral skull X-ray showing classic punched-out lytic lesions of multiple myeloma
Gross pathology of calvaria with multiple myeloma lytic lesions

4. Staging

International Staging System (ISS) - based on β2M and albumin

StageCriteriaMedian Survival
Iβ2M <3.5 mg/L AND albumin ≥3.5 g/dL~62 months
IINeither I nor III~44 months
IIIβ2M ≥5.5 mg/L~29 months
β2M is the single most powerful predictor of survival and can substitute for staging. - Harrison's 22E

Revised ISS (R-ISS) - adds cytogenetics and LDH

StageCriteria
R-ISS IISS Stage I + standard-risk FISH + normal LDH
R-ISS IINeither I nor III
R-ISS IIIISS Stage III + high-risk FISH or elevated LDH
Note: The older Durie-Salmon system is no longer used to predict outcome in the era of novel agents. - Harrison's 22E

5. Cytogenetic Risk Stratification (FISH/DNA Sequencing)

This is one of the most important steps - it directly impacts prognosis and, increasingly, treatment choice.
RiskFeatures
Standard risk (75-80%; expected survival 8-10+ years)t(11;14), del(13q), hyperdiploidy
High risk (20-25%; expected survival 3-4 years)del(17p) with ≥20% clonality, TP53 mutation, t(4;14), t(14;16), t(14;20) with 1q gain or 1p deletion, del(1p) + 1q gain, biallelic del(1p)
  • Current recommendation is DNA sequencing as the preferred method; FISH if sequencing is unavailable
  • Chromosome 13q deletion and t(11;14) are not considered high-risk predictors
  • β2M >5.5 with normal creatinine (suggesting tumor burden, not renal-related elevation) also signals high risk
(Source: Harrison's Principles of Internal Medicine 22E, Table 116-3)

6. Transplant Eligibility Assessment

All patients <70-75 years (and some older, fit patients) should be assessed for autologous hematopoietic stem cell transplantation (ASCT) eligibility, which is still standard of care after induction:
  • Performance status (ECOG/KPS)
  • Cardiac evaluation (echo/ECG)
  • Pulmonary function tests
  • Renal function (affects high-dose melphalan conditioning)
  • Absence of uncontrolled infection
Prospective trials confirm that early ASCT, when feasible, remains standard of care even in the era of triple-drug novel agent regimens. - Goldman-Cecil Medicine

7. Summary Workup Checklist

Routine (all patients):
  • SPEP, serum IFE, serum free light chains (FLC)
  • 24-hr urine PEP + IFE
  • Quantitative Ig levels
  • CBC, CMP (Ca, Cr, albumin), LDH, CRP
  • β2-microglobulin
  • Bone marrow aspirate + core biopsy (with FISH or DNA sequencing panel)
  • Whole-body low-dose CT (or MRI if CT negative/equivocal)
Selected cases:
  • PET-CT - extramedullary disease or nonsecretory myeloma
  • Whole-body MRI - suspected cord compression, MRI-defined focal lesions
  • Serum viscosity - IgM or IgA M component or M protein >7 g/dL
  • Abdominal fat pad biopsy - suspected concurrent AL amyloidosis
  • Myd88/CXCR4 mutation analysis - if IgM component present (to rule out Waldenstrom's)

Recent Evidence Note

Two important 2025 guidelines have been published that may update practice:
These may update specific cut-offs or add new biomarkers - check these if you are making clinical decisions.
This is a shared conversation. Sign in to Orris to start your own chat.